217 related articles for article (PubMed ID: 26271806)
1. Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
Trembath L; Newell M; Devous MD
J Nucl Med Technol; 2015 Sep; 43(3):175-84. PubMed ID: 26271806
[TBL] [Abstract][Full Text] [Related]
2. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
3. Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images.
Carbonell F; Zijdenbos AP; Charil A; Grand'Maison M; Bedell BJ;
J Nucl Med; 2015 Sep; 56(9):1351-8. PubMed ID: 26135108
[TBL] [Abstract][Full Text] [Related]
4. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
[TBL] [Abstract][Full Text] [Related]
5. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N; Yanai K
IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
[TBL] [Abstract][Full Text] [Related]
6. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.
Lin KJ; Hsu WC; Hsiao IT; Wey SP; Jin LW; Skovronsky D; Wai YY; Chang HP; Lo CW; Yao CH; Yen TC; Kung MP
Nucl Med Biol; 2010 May; 37(4):497-508. PubMed ID: 20447562
[TBL] [Abstract][Full Text] [Related]
7. Use of florbetapir-PET for imaging beta-amyloid pathology.
Clark CM; Schneider JA; Bedell BJ; Beach TG; Bilker WB; Mintun MA; Pontecorvo MJ; Hefti F; Carpenter AP; Flitter ML; Krautkramer MJ; Kung HF; Coleman RE; Doraiswamy PM; Fleisher AS; Sabbagh MN; Sadowsky CH; Reiman EP; Zehntner SP; Skovronsky DM;
JAMA; 2011 Jan; 305(3):275-83. PubMed ID: 21245183
[TBL] [Abstract][Full Text] [Related]
8. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
[TBL] [Abstract][Full Text] [Related]
9. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
[TBL] [Abstract][Full Text] [Related]
10. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
11. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
[TBL] [Abstract][Full Text] [Related]
12. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
13. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
14. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
15. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
[TBL] [Abstract][Full Text] [Related]
16. Radiation dosimetry and pharmacokinetics of florbetapir (
Nakano M; Nakamura T; Takita Y; Uenaka K; Ando T; Senda M; Joshi AD; Lu M; Breault C; Pontecorvo MJ
Ann Nucl Med; 2019 Aug; 33(8):639-645. PubMed ID: 31140155
[No Abstract] [Full Text] [Related]
17. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.
Yao CH; Lin KJ; Weng CC; Hsiao IT; Ting YS; Yen TC; Jan TR; Skovronsky D; Kung MP; Wey SP
Appl Radiat Isot; 2010 Dec; 68(12):2293-7. PubMed ID: 20638295
[TBL] [Abstract][Full Text] [Related]
18. Is in vivo amyloid distribution asymmetric in primary progressive aphasia?
Martersteck A; Murphy C; Rademaker A; Wieneke C; Weintraub S; Chen K; Mesulam MM; Rogalski E;
Ann Neurol; 2016 Mar; 79(3):496-501. PubMed ID: 26600088
[TBL] [Abstract][Full Text] [Related]
19. Florbetapir-PET imaging and postmortem beta-amyloid pathology.
Carome M; Wolfe S
JAMA; 2011 May; 305(18):1857; author reply 1857-8. PubMed ID: 21558513
[No Abstract] [Full Text] [Related]
20. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
Rominger A; Brendel M; Burgold S; Keppler K; Baumann K; Xiong G; Mille E; Gildehaus FJ; Carlsen J; Schlichtiger J; Niedermoser S; Wängler B; Cumming P; Steiner H; Herms J; Haass C; Bartenstein P
J Nucl Med; 2013 Jul; 54(7):1127-34. PubMed ID: 23729696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
